ASCO 2024 preview – conjugates in focus
This weekend’s oncology conference will feature at least 30 different ADC projects.
BeiGene takes a new approach to a hot target
Meanwhile Bristol’s Orum-originated project goes into the clinic, and Miltenyi looks to challenge Syndax and Kura.
ASCO 2024 preview – Astra’s plenary double
Abstract titles reveal some of ASCO’s key datasets.
Merck matches Kelun’s saci-tirumo efforts
Three recently added trials take Merck & Co’s tally of phase 3 sacituzumab tirumotecan studies to six.
Merck’s latest move is in bispecifics
A $680m swoop for Harpoon will fill a hole in Merck’s pipeline.
Merck’s conjugates dominate pivotal trial initiations
Raludotatug deruxtecan, ABBV-383 and zongertinib advance into phase 3, while other pivotal programmes are expanded.
Like Merck, Bristol goes to China
Yet another rich ADC deal is struck as Bristol Myers Squibb ties up with China’s SystImmune.
